How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,290 results for

Aphasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3681. Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)

( Genzyme, a Sanofi Company ): Acid sphingomyelinase deficiency Niemann-Pick disease Lysosomal storage disorder Enzyme replacement therapy Treatment Additional relevant MeSH terms: Layout table for MeSH terms Pick Disease of the Brain Aphasia, Primary Progressive Frontotemporal Dementia Niemann-Pick Diseases Niemann-Pick Disease, Type A Niemann-Pick Disease, Type C Frontotemporal Lobar Degeneration Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurocognitive Disorders (...) Mental Disorders Aphasia Speech Disorders Language Disorders Communication Disorders Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms TDP-43 Proteinopathies Neurodegenerative Diseases Proteostasis Deficiencies Metabolic Diseases Sphingolipidoses Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Histiocytosis, Non-Langerhans-Cell Histiocytosis

2006 Clinical Trials

3682. Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

with ADLs; life threatening, disabling. Number of Participants With the Indicated Investigator Assessment of Language (Dysphasia or Aphasia) at Baseline, Month 1, and Month 3 [ Time Frame: Baseline, Month 1, and Month 3 ] The investigator assessed participants' status of language (dysphasia or aphasia) and assigned each participant to one of the following categories: absent; awareness of receptive or expressive aphasia, not impairing ability to communicate (not impaired); receptive or expressive (...) dysphasia, impairing ability to communicate (impaired); inability to communicate (unable). Number of Participants With the Indicated Investigator Assessment of Strength (Right Upper Extremity) at Baseline, Month 1, and Month 3 [ Time Frame: Baseline, Month 1, and Month 3 ] The investigator assessed participants' status of strength (right upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2

2006 Clinical Trials

3683. The Stroke Warning Information and Faster Treatment Study (SWIFT)

: Patients unable to give informed consent Discharged to nursing home or requiring 24 hour care. A Modified Rankin score > 4 at baseline Severe aphasia or severe cognitive impairment limiting comprehension Pre-stroke dementia history Patients with end stage cancer, or other medical conditions resulting in mortality

2006 Clinical Trials

3684. A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia

Behavioral Inventory during the randomized withdrawal period. In addition, for subjects with primary progressive aphasia (limited ability for languages), the effects of galantamine on language will be explored using the Aphasia Quotient of the Western Aphasia Battery, and for all subjects the Clinical Global Impressions will be used to explore global change. Condition or disease Intervention/treatment Phase Frontotemporal Dementia Pick Complex Drug: galantamine hydrobromide Phase 2 Study Design Go (...) for eligibility information Ages Eligible for Study: 30 Years to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Outpatients with a clinical diagnosis of Frontotemporal Dementia or Pick Complex (PC/FTD) documented for at least 1 year with either primary progressive aphasia or frontotemporal dementia recent MRI or CT confirming frontotemporal lobar atrophy consistent with Frontotemporal Dementia or Pick Complex PC/FTD opportunity

2006 Clinical Trials

3685. Effect of Parecoxib on Post-craniotomy Pain

Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Supratentorial craniotomy, glasgow coma scale 15 Exclusion Criteria: Chronic pain, Chronic opioid use. History of significant alcohol or benzodiazepine (BZD) use, Inability to speak English, Pre-operative aphasia or dysphasia, Renal impairment (Creatinine level > 0.1), Asthma (or evidence of reversible airway obstruction, Known ischaemic heart disease or cerebrovascular

2007 Clinical Trials

3686. Treadmill Exercise Prescriptions to Improve Fitness Versus Ambulatory Function After Stroke.

mellitus (fasting glucose greater than 180 mg/dl, HgA1C greater than 10%) unable to be controlled medically within 3 months; g) Anemia defined by hematocrit less than 30 . (5) Neurological history of dementia with Mini-Mental Status Score less than 23 (less than 17 if education level at or below 8th grade), and diagnostic confirmation by neurologist or psychiatrist, severe receptive or global aphasia which confounds testing and training, operationally defined as unable to follow 2 point commands

2007 Clinical Trials

3687. Screening and Treatment of Depression in the Community

Inclusion Criteria: > 60 years without dementia, Major depressive disorder, Bipolar disorder, Dysthymia disorder, Anxiety disorder, Mania/hypomania Exclusion Criteria: Severe post-stroke dementia or aphasia, History of mania, psychiatric consultation or admission to hospital in past 3 months, MMSE score <18, Fully dependent at 3 or more basic activities of daily living, Very high BDI score (>=30), Serious suicidal risk, Current psychotic symptoms, Current alcohol abuse, Very high GDS score (>=12

2007 Clinical Trials

3688. Shoulder, or Elbow, or Wrist: What Should we Train First After a Stroke?

instructions (Mini-Mental Status Score of 22 and higher or interview for aphasic subjects); average Motor Power score >= 1/5 or <= 3/5 (neither hemiplegic nor fully recovered motor function in 6 muscles of the shoulder, elbow, and wrist); informed written consent to participate in the study. Exclusion Criteria: Patients will be excluded from the study if they have a fixed contraction deformity in the affected limb. Contacts and Locations Go to Information from the National Library of Medicine To learn more

2007 Clinical Trials

3689. Benefits of Applying Neuroprosthesis for Improving Reaching and Grasping Functions in Stroke Patients

and the stroke must be confirmed with a CT scan. Patients must understand that the role of this study is to enhance recovery and not to guarantee it. Exclusion Criteria: Patients who is motivated and does not sign the letter of consent. Patient who has serious cognitive or psychological impairments. Patients who has skin rush, allergy or wounds. Alcohol or drug abuse. Edema in his/her upper extremity. Patients with Shoulder Hand Syndrome Global aphasia Patients who shows early recovery of the function

2005 Clinical Trials

3690. Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy

and diurnal seizures consisting of simple partial seizures consisting of brief unilateral facial clonic activity, dysphasia, and drooling. The EEG abnormalities are unique, consisting of generally high amplitude, centrotemporal spikes that are activated by sleep. The seizures typically begin in the first decade and almost always stop by age 16 years. The seizures are usually infrequent although clusters of seizures do occur. When the physician elects to treat, the seizures are usually easily controlled

2005 Clinical Trials

3691. Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

: No Criteria Inclusion Criteria: Diagnosis of Alzheimer's type dementia, rated as severe progressive worsening of memory and other cognitive functions brain imaging (CTor MRI scan) within last 3 years ability to be mobile (aided or unaided) with sufficient vision and hearing to comply with testing. Exclusion Criteria: Dementia caused by cerebrovascular disease disturbances of consciousness, delirium, psychosis severe aphasia or major sensorimotor impairment cognitive impairment due to acute cerebral trauma

2005 Clinical Trials

3692. Affect Recognition: Enhancing Performance of Persons With Acquired Brain Injury (ABI)

impairment. Perceptual impairment (visual neglect and/or visual discrimination). Impaired verbal expression/ aphasia Alcohol or substance abuse. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00283153 Locations Layout table for location information

2006 Clinical Trials

3693. A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

than 1/3 hemisphere Patient having a score below the cut-off point at Frenchay Aphasia Short Test Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00276380 Locations Layout table for location information Czechia Faculty of Medicine in Hradec Kralove

2006 Clinical Trials

3694. Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

as defined below: Peripheral lymphocyte count > 20 x 10^9/L Platelet counts ≤ 75,000/µL Hemoglobin level ≤ 9 g/dL Venous pH value out of normal range or oxygen saturation ≤ 90% Known or suspected central nervous system (CNS) involvement by NHL a)History of or current relevant CNS pathology as epilepsy, seizure, paresis,aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis b)Evidence for presence of inflammatory lesions and/or vasculitis on cerebral MRI

2006 Clinical Trials

3695. Headache Study to Compare Aggrenox Full Dose and Reduced Dose

Criteria: Patients with known or suspected prior intracranial haemorrhage or history of brain injury or brain tumor. Disorders related to syncope, drop attacks, congenital vascular malformation, aneurysm, angioma, or epilepsy, psychiatric disorders. Peptic ulcer or gastrointestinal bleeding within 6 months. History of hypersensitivity or intolerance to study drugs or aspirin. Experienced habitual headache (any form) within the past 3 months. History of dysphasia, dysphagia, dementia, or unconsciousness

2006 Clinical Trials

3696. The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression

, hypothyroidism, or uncontrolled diabetes Significant acute neurologic illness including: impaired consciousness, Parkinson's disease, Huntington's chorea, progressive supranuclear paralysis, brain tumor, subdural hematoma, multiple sclerosis, hydrocephalus, Binswanger's disease, or severe aphasia Presence of a premorbid Axis I psychiatric diagnosis (eg. schizophrenia, bipolar disorder) Depressed group only: contraindications to receiving treatment with citalopram (including previous nonresponse) or serious

2005 Clinical Trials

3697. mCIMT and Eye Patching for Neglect Rehabilitation Post Stroke: A Longitudinal Study of Separate and Combined Effects

part movement in the affected upper extremity and a minimum of 20 degrees of active wrist extension and 10 degrees of finger extension; (4) no severe aphasia that hampers command following; (5) no severe cognitive impairments (Mini-Mental State Examination score >= 22); (6) being right-handed premorbidly by self-report. Exclusion Criteria: Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research

2005 Clinical Trials

3698. VA Low Vision Intervention Trial

therapist or vision rehabilitation professional since most recent significant decrease in vision has English literacy less than 5th grade level has habitual visual acuity in better seeing eye of equal to or better than 20/100, less than or equal to 20/500 fails Telephone Interview of Cognitive Status (TICS) screening (score of 30 or lower) has history of stroke with aphasia has other health condition that would preclude follow-up (e.g. significant malignancy or life-threatening disease) is unable

2005 Clinical Trials

3699. Vestibular Stimulation to Treat Hemispatial Neglect

of aphasia on clinical examination (crossed aphasia) A significant history of other neurological or psychiatric illness or drug/alcohol abuse Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00271388 Locations Layout table for location information United

2005 Clinical Trials

3700. Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)

of symptoms (for un-witnessed stroke, last time seen in normal state or at bedtime for un-witnessed stroke during sleep) Signed informed consent from subject or legally acceptable representative NIHSS score of 6 - 22, inclusive, or at least 2 on the aphasia item of the NIHSS with a location of MRI findings consistent with aphasia MRI-determined inclusion criteria: Acute ischemic stroke with substantial cortical involvement in the middle cerebral artery (MCA) distribution, as verified by the Screening DWI

2006 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>